Novartis

Why Novartis CEO ended his ADC holdout for $1.5B Myricx deal

After years without any notable ADC deals, Novartis CEO Vas Narasimhan explains why a $1.5 billion bet on Myricx Bio’s novel payload changed his mind.

Angus Liu Jul 21, 2026 1:26pm

Novartis drops ph. 2-stage radioligand therapy over poor data

Jul 21, 2026 8:18am

Novartis to pay $1.1B upfront for Myricx to expand ADC pipeline

Jul 6, 2026 5:10am

Evommune’s phase 2b flops, ending challenge to Novartis in hives

Jun 29, 2026 10:00am

Antares and Rho Ophiuchi cloud complex in the Sagittarius constellation

Novartis pays Antares $105M to tackle undruggable cancer targets

Jun 24, 2026 9:13am

Novartis dystrophy data tee up regulatory talks on Avidity drug

Jun 12, 2026 4:30am